News & Updates
Filter by Specialty:

Fezolinetant eases symptoms in menopausal women unfit for hormone therapy
04 Dec 2024
byStephen Padilla
Use of fezolinetant demonstrates efficacy and good tolerability in the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women who are deemed unsuitable for hormone therapy, reports a study.
Fezolinetant eases symptoms in menopausal women unfit for hormone therapy
04 Dec 2024
ADA 2022 guidelines improve prescribing rates of SGLT2 inhibitors in T2D patients
02 Dec 2024
The overall utilization rates of SGLT2 inhibitors have increased among patients with type 2 diabetes (T2D) following the release of the 2022 American Diabetes Association (ADA) guidelines.